Clinical Trials Logo

Hypersensitivity clinical trials

View clinical trials related to Hypersensitivity.

Filter by:

NCT ID: NCT05382975 Recruiting - Physical Activity Clinical Trials

A Comprehensive Trauma-sensitive Approach to Physical Activity Promotion in Schools (CSPAP-T)

CSPAP-T
Start date: August 1, 2022
Phase: N/A
Study type: Interventional

Investigators will conduct a hybrid implementation-effectiveness trial of a trauma-adapted Comprehensive School Physical Activity Program (CSPAP) intervention. A clustered stepped wedge design will be used, with the duration of the trial being 3 years.

NCT ID: NCT05381311 Completed - Prostate Cancer Clinical Trials

Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study

Start date: September 3, 2021
Phase:
Study type: Observational

The purpose of this study is to quantify and publish participants' relative preferences for outcomes of chemotherapy and novel oral hormonal agents when added to androgen deprivation therapy (ADT) for participants with locally-advanced and metastatic hormone-sensitive prostate cancer (mHSPC). This study will also quantify the importance of administration factors related to convenience relative to treatment outcomes.

NCT ID: NCT05378217 Completed - Clinical trials for Antimicrobial Drug Resistance

AMR-DetecTool for the Diagnostic of MDR Bacterial Infections

AMR DetecTool
Start date: July 18, 2022
Phase:
Study type: Observational

The fight against bacteria is one of the greatest challenges faced by societies, especially with the spread of multi drug resistant (MDR) bacteria. The failure to stop the spread of antimicrobial resistance (AMR) is due to a lack of fast detection methods and proper strategies. Novel, rapid and reliable detection and characterization tests are an urgent need for differentiating between bacterial and viral infections and identifying AMR, so that the most appropriate treatment can be given in a timely manner. AMR-DetecTool or NG Detectool is a detection system for the direct detection of AMR in clinical samples. The clinical sample is directly processed and a result indicating if the bacteria are resistant to the most relevant antibiotics is immediately shown. It allows for a dramatic reduction in the treatment decision time upon sample reception from 24 hours (current workflow) to 15-30 minutes.

NCT ID: NCT05378074 Recruiting - Clinical trials for Post-Traumatic Headache

Hypersensitivity to Opening of BKCa Channels in Post-Traumatic Headache

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The aim is to investigate whether opening of large conductance calcium-activated potassium (BKCa) channels induces headache with migraine-like features in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).

NCT ID: NCT05378061 Recruiting - Clinical trials for Post-Traumatic Headache

Hypersensitivity to PACAP-38 in Post-Traumatic Headache

Start date: June 16, 2022
Phase: N/A
Study type: Interventional

The aim is to investigate whether signaling molecule PACAP-38 induces headache with migraine-like features in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).

NCT ID: NCT05370417 Not yet recruiting - Clinical trials for Hypomineralization Molar Incisor

Photobiomodulation and Glass Ionomer Sealant as Complementary Treatment for Hypersensitivity in Molars With MIH

Start date: October 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Photobiomodulation has been widely used as complementary treatment for dentin hypersensitivity, with reports of clinical success. However, the literature offers only one study in which photobiomodulation was used for the treatment of sensitivity in molars with molar incisor hypomineralization (MIH). The aim of the proposed study is to determine whether photobiomodulation enhances the results of treatment with glass ionomer sealant on molars with MIH that present sensitivity. Methods and analysis: The study involving 50 patients 6 to 12 years of age tha will be randomly allocated in two groups. Group 1 (control group) (n = 25): toothpaste with a concentration of fluoride, glass ionomer sealant and sham low-level laser (LLL) and Group 2 (n = 25): toothpaste with a concentration of fluoride, glass ionomer sealant and active low-level laser (LLL). The evaluations will involve MIH record, Simplified Oral Hygiene Index (OHI), Schiff Cold Air Sensitivity Scale (SCASS) and Visual analog scale (VAS) before the procedure. Immediately after the procedure hypersensitivity index (SCASS/VAS) will be register. Record of OHI and SCASS/VAS will be register 48 horas after and as well as 01 month after the procedure. It is expected that by the second consultation a decrease in sensitivity will be observed due to the treatments received in the two groups.

NCT ID: NCT05367531 Recruiting - Bleeding Clinical Trials

Assessment of Injectable Medication Platforms

Start date: April 30, 2022
Phase: N/A
Study type: Interventional

Background: While medical advances for in-hospital care rapidly evolve, a mainstay of effective pre-hospital care remains the ability to treat medical emergencies such as anaphylaxis, prolonged seizure, overdose, or uncontrolled bleeding, through rapid administration of appropriate medication. Autoinjectors are used globally to deliver medications in a timely manner, often in environments where immediate access to medical facilities is limited. Rapid administration of intramuscular medication delivery is essential where oral or intravenous delivery is either not possible or ineffective. The purpose of the proposed study seeks to determine the efficiency various types of medication injection administration.

NCT ID: NCT05365802 Recruiting - Clinical trials for Interstitial Lung Disease

FAPI PET for Lung Fibrosis

FAPI ILD
Start date: November 16, 2021
Phase: Early Phase 1
Study type: Interventional

This is a prospective exploratory biodistribution study in patients with interstitial lung disease (ILD). The purpose of this research study is to determine where and to which degree the FAPI tracer (68Ga-FAPI-46) accumulates in normal and fibrotic lung tissues of patients with interstitial lung disease. The study will include patients with interstitial lung disease who have or will initiate a new ILD medication OR will undergo tissue biopsy or surgery of the lung. The study will include 30 patients, the upper limit for PET imaging studies conducted under the Radioactive Drug Research Committee (RDRC) purview. Participants will be injected with up to 7 mCi of 68-GaFAPi and will undergo one PET/CT scan and one High Resolution CT of the lungs. The study is sponsored by Ahmanson Translational Theranostic Division at UCLA.

NCT ID: NCT05365295 Completed - ADHD Clinical Trials

Study of ADHD Children's Sensitivity to Memory Error Production

TDAH-DRM
Start date: June 28, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to test whether children with Attention Deficit/Hyperactivity Disorder (ADHD) are more susceptible to false memory production using a DRM paradigm. The number of "critical decoy production" errors will be analyzed and compared to the calibration of the test.

NCT ID: NCT05346718 Recruiting - Allergic Rhinitis Clinical Trials

Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis

UBAMBI
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The ragweed Ambrosia artemisiifolia is spreading in northern Europe due to climate change. The pollen are considered highly allergenic and might trigger allergy symptoms at much lower concentrations than e.g. grass or birch pollen. This study aims to determine threshold concentrations for ragweed and birch pollen in patients with seasonal allergic rhinitis. Participants will be exposed in an allergen challenge chamber that was technically modified to maintain very low and stable pollen concentrations for several hours. The study design is adaptive, where the pollen concentrations are escalated or de-escalated based on interim analysis of resulting allergic symptoms.